This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA)

This study has been terminated.
Information provided by:
DeveloGen Israel, Ltd. Identifier:
First received: April 15, 2003
Last updated: March 18, 2009
Last verified: March 2009
Randomized, double-blind, parallel-group study to evaluate safety and efficacy of multiple subcutaneous doses of DiaPep277 in patients with Latent Autoimmune Diabetes in Adults (LADA). Study medication will be administered at time 0, 1 and 3 months, and then every 3 months for a total of 8 administrations. The total duration of the trial is 24 months (treatment for 18 months and follow-up for an additional 6 months). Patients will be male or female between the ages of 30 and 65 years, inclusive, within 2 to 60 months of the diagnosis of diabetes mellitus. Subjects must be positive for glutamic acid decarboxylate (GAD) autoantibodies. At the Screen Visit (Visit 2), all subjects will be asked to discontinue their use of all oral antidiabetic medications with the exception of metformin. The subjects will be placed on a stable regimen of insulin and diet (plus metformin if needed). Prior to the Baseline Visit (Visit 3), diabetic control must be achieved by diet and insulin (plus metformin if needed).

Condition Intervention Phase
Diabetes, Autoimmune Drug: DiaPep277 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety and Tolerability as Well as the Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in LADA Subjects

Resource links provided by NLM:

Further study details as provided by DeveloGen Israel, Ltd.:

Estimated Enrollment: 100
Study Start Date: October 2002
Study Completion Date: May 2007
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   30 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

Subjects meeting all of the following inclusion criteria at screening should be considered for admission to the study:

  • The subject has a diagnosis of diabetes mellitus according to WHO classification for more than 2 months and less than 5 years before enrollment.
  • The subject's diabetes has been controlled by diet and insulin (plus metformin if needed) for 2 or more weeks (14 days) prior to the Baseline Visit (Visit 3).
  • The subject is a male or female aged 30 to 65 years. If female and not postmenopausal, the subject is not pregnant and will use effective contraceptive methods throughout the study.
  • The subject is positive for GAD autoantibodies, defined as a level greater than the 99th percentile of the GAD antibody index of a normal control population for the laboratory (e.g., GAD antibody index equal to 0.085).
  • The subject has a fasting C-peptide level 0.30 nmol/L or greater or 0.9 ng/mL at the time of the Screen Visit (Visit 1 or 2).

Exclusion Criteria

Subjects meeting any of the following exclusion criteria at screening will not be enrolled in the study:

  • The subject has any significant diseases or conditions, including psychiatric disorders and substance abuse that, in the opinion of the site investigator, are likely to affect the subject's response to treatment or their ability to complete the study.
  • The subject has a history of any kind of malignant tumor.
  • The subject has secondary diabetes mellitus.
  • Within 2 weeks or 14 days of the Baseline Visit or during randomized treatment, the subject takes an oral anti-diabetic medication other than metformin to treat his/her diabetes.
  • The subject has clinical evidence of any diabetes-related complication that in the opinion of the site investigator would interfere with the subject's participation in and/or completion of the study.
  • The subject has a history of allergy or asthma that in the opinion of the site investigator would interfere with the subject's participation in and completion of the study.
  • The subject has a known immune deficiency from any disease, or a condition associated with an immune deficiency.
  • The subject is receiving immunosuppressive or immunomodulating agents or cytotoxic therapy, or any medication that, in the opinion of the site investigator, might interfere with the study.
  • The subject is a pregnant woman or a woman who is planning to become pregnant.
  • The subject has any of the following:

    • chronic hepatitis or liver cirrhosis, or any other chronic liver disease
    • is known to test positive for hepatitis B antigens or hepatitis C antibodies
    • has abnormal liver function, defined as serum AST or ALT 3 times or more the upper limit of normal
  • The subject is a known or suspected drug abuser.
  • The subject has influenza-like symptoms on the day of dosing.
  • The subject is known to test positive for HIV antibodies.
  • The subject has chronic hematologic disease.
  • The subject has impaired renal function (serum creatinine greater than 1.4 mg/dL).
  • The subject has severe ketonuria (+++ on urine stix testing; ++ on repeated urine stix testing).
  • The subject has a BMI greater than 40kg/m2.
  • The subject has hyperlipidemia (fasting serum triglycerides >1000 mg/dL). Suitable medical therapy for treatment of hyperlipidemia is allowed.
  • The subject has received any investigational drug within 3 months prior to Visit 1.
  • The subject has had a severe blood loss (400 mL or more, e.g., blood donation) within 2 months before the first dosing of the study medication.
  • The subject is a breast-feeding mother or planning to breast-feed.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00058981

United States, Alabama
University of Alabama at Birmingham Endocrinology Department
Birmingham, Alabama, United States, 35294
United States, Colorado
University of Colorado Hospital Endocrinology Practice
Aurora, Colorado, United States, 80010
United States, Kentucky
University of Kentucky Department of Internal Medicine
Lexington, Kentucky, United States, 40536
United States, Missouri
Washington University School of Medicine Endocrinology/Metabolic Dept
Saint Louis, Missouri, United States, 63110
United States, New York
North Shore Diabetes and Endocrine Associates
New Hyde Park, New York, United States, 11042
United States, Texas
Diabetes & Glandular Disease Research Associates
San Antonio, Texas, United States, 78229-4801
United States, Washington
DVA Puget Sound Health Care System Endocrinology (III) Department
Seattle, Washington, United States, 98108
Sponsors and Collaborators
DeveloGen Israel, Ltd.
Principal Investigator: Jerry P Palmer, MD University of Washington
Study Director: Dana Elias, PhD DeveloGen Israel, Ltd.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00058981     History of Changes
Other Study ID Numbers: 702/PO
Study First Received: April 15, 2003
Last Updated: March 18, 2009

Keywords provided by DeveloGen Israel, Ltd.:
latent autoimmune diabetes in adults

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases processed this record on June 22, 2017